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Particulate vector systems for the presentation of immunogenic epitopes provide an alternate and powerful approach for the
delivery of immunogens of interest. In this article, we have exploited a viral protein of unknown function, bluetongue virus (BTV)
nonstructural protein NS1, which forms distinct tubular aggregates in infected cells, as an immunogen delivery system. Tubules
are helical assemblies of NS1 protein that present the C-terminus of the protein to the outer edge effectively displaying appended
residues in a regular and repeating array akin to the coat of a filamentous phage. To assess the breadth of response induced
following tubule-based immunization, two different immunodominant foreign peptides were inserted at the C-terminus of NS1 and
chimeric tubules generated following expression in the baculovirus expression system. Both constructs, one carrying a peptide of
foot and mouth disease virus (FMDV) (aa 135–144 of VP1) and the other, a peptide of influenza A virus (aa 186–205 of HA),
effectively assembled into tubules and were easily purified. Subsequently, using in vitro assay systems, we demonstrated that each
purified chimeric particle was capable of eliciting strong immune responses. Further, NS1-FMDV chimeric tubules could induce aINTRODUCTION
Attempts to enhance the immunogenicity of antigens for
use as vaccines have led to the development of a number
of antigen presentation systems. Various vaccines based
on the major immunodominant epitopes of a virus have
been developed that alleviate problems associated with
“whole” virus vaccines (Nardelli and Tam, 1995; Ben-Yedidia
and Arnon, 1997). However, protection with such systems
often requires multiple rounds of immunization and is gen-
erally strain specific (Brown et al., 1992). Enhancement of
the immune response has been shown to occur when
immunodominant epitopes are presented to the immune
system in a multiple array displaying on the surface of a
complex carrier such as on the hepatitis B virion (Clarke et
al., 1987). However, the molar proportion of the immune
active component to the carrier is often very low and the
complexity of production also limits useful application.
Moreover, similar to the hepatitis B virus, many virus cap-
sid-based delivery systems have limitations in their capac-
ity to accommodate foreign sequences due to packaging
constraints (Adams et al., 1987; Clarke et al., 1987; Evans et
al., 1989; French and Roy, 1990; Belyaev and Roy, 1993;
Griffiths et al., 1993; LeBlois and Roy, 1993; Miyamura et al.,
1994; Adler et al., 1998).383The nonstructural protein NS1 of bluetongue virus
(BTV) multimerizes into stable tubular structures in in-
fected cells, the role of which is unclear. The tubules are
approximately 52.3 nm in diameter and up to 1000 nm in
length and are composed of helically coiled ribbons of
NS1 “dimers,” with 21 or 22 dimers per turn (Hewat et al.,
1992).
Previously, we localized a major antigenic site at the
C-terminus of the NS1 protein of BTV (Monastyrskaya et
al., 1995) and, as this site is exposed on the surface of
the tubule suggested, it could potentially incorporate
considerably large foreign sequences for immune pre-
sentation without perturbing the helical structures. In-
deed, when C-terminus was manipulated to insert extra
sequences, it was possible to generate chimeric tubules
carrying large foreign polypeptides (Mikholov et al.,
1996).
In this article we wanted to determine whether such
particles could elicit immune responses. To this end we
have used two established immunogenic epitopes, one
derived from VP1, the antigenic protein of foot and mouth
disease virus (FMDV), and the other, from the hemagglu-
tinin (HA) protein of influenza A virus, to generate chi-
meric NS1 tubules. The rationale for selection of these
two epitopes is that while the FMDV VP1 peptide (aa
135–144) has been documented to elicit a particularpotent immune response that could protect against disease.
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humoral response (Zamorano et al., 1994), the HA pep-
tide (aa 186–205) has been reported to elicit cell-medi-
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ated immunity (Fox et al., 1989). Chimeric tubules were
expressed by recombinant baculoviruses; purified and
appropriate in vitro and in vivo immune responses
against each peptide were assessed. In addition, follow-
ing immunization, the protective efficacy of NS1-FMDV
chimera was determined by a virulent virus challenge in
mouse model system. Our data showed that purified
chimeric tubules induce both humoral and cell-mediated
responses and suggest that tubule-based vaccines offer
significant advantage for the induction of broad ranging
immune responses with the potential for protection.
RESULTS
Recombinant baculovirus-derived chimeric NS1
proteins generate tubular structures in insect cells
Two different chimeric constructs were designed, one
to assess the CD4 Th response and the other to assess
protective humoral immune response. Therefore, two re-
combinant baculovirus transfer vectors, one containing
the VP1 sequence (aa 135–144) of FMDV and the other
containing the influenza A HA sequence (aa 186–205)
downstream of NS1 gene were constructed and recom-
binant baculoviruses were generated as described un-
der Materials and Methods. The level of chimeric protein
expression of each protein was monitored by SDS–PAGE
analysis from insect cells infected with each recombi-
nant virus. As shown in Fig. 1A both recombinant viruses
expressed high level of chimeric NS1 protein (lanes c
and d) and that the level of expression of each chimeric
protein was as high as the wild-type NS1 expression
(lane e). The origin and authenticity of each protein band
was confirmed by Western blot analysis using an anti-
NS1 mouse serum. While both chimeric bands and the
wild-type NS1 band were detected by anti-NS1 anti-
serum (Fig. 1B, lanes b and c), only the chimeric NS1
tubules were reacted with antiserum specific for FMDV
peptide (Fig. 1C, lane a), or anti-HA antibody (data not
shown).
Formation of tubular structure by chimeric NS1
protein
As immune stimulation by NS1 fusion proteins re-
quires the formation of chimeric NS1 tubules, each of the
recombinant virus-infected insect cells were examined
for their capabilities to form NS1-like tubules by electron
microscopy. Sections of infected cells showed the accu-
mulation of tubules as seen for previously reported re-
combinant NS1 tubules (Urakawa and Roy, 1988), dem-
onstrating that the insertion of either FMDV VP1 peptide
or the HA peptide does not perturb the tubular morphol-
ogy (data not shown). The tubule-forming capability of
the fusion protein was further characterized by biochem-
ical methods. Since NS1 tubules could be readily iso-
lated by sucrose gradient centrifugation (Urakawa and
Roy, 1988), insect cells infected with the recombinant
baculoviruses were lysed and the cytoplasmic extracts
sedimented through a 10–40% sucrose gradient. To pro-
vide a positive control, NS1 tubules representing the
wild-type protein were similarly processed. Each su-
crose gradient was fractionated and aliquots from each
fraction were analyzed by SDS–PAGE. Both wild-type
NS1 and the chimeric NS1 products detected in broad
bands were present predominantly in fractions 3 to 7 of
each gradient (Fig. 2A). When peak fractions of each
sample were analyzed by SDS–PAGE, only a single pro-
tein band was present in each case, confirming that
tubules were highly purified (Fig. 2B). Further, when frac-
tions of each gradient containing NS1 tubules were ex-
FIG. 1. Expression of chimeric NS1 proteins in Sf-9 cells by recombinant baculoviruses. (A) Extracts obtained from AcNS1.FMDV VP1 (135–144) and
AcNS1.Flu HA (186–205) virus-infected cells (lanes c and d, respectively) were separated by 10% SDS–PAGE and stained. Mock-infected cell extracts
(lane a), and wild-type NS1 proteins, to indicate the level of expression, obtained from Ac10BTV6 baculovirus infected cells (lane e) are also shown.
Purified wild-type NS1 protein (lane b) served as a reference marker. (B) Western immunoblotting of chimeric NS1-influenza HA protein expression
in AcNS1.HA (186–205) recombinant baculovirus-infected Sf-9 cell extracts by anti-NS1 mouse serum. Both wild-type NS1 (lane b) and NS1-influenza
A HA (186–205) (lane c) proteins were recognized but not mock-infected cell extracts (lane a). (C) Western immunoblotting of chimeric NS1-FMDV VP1
(aa 135–144) expression in Sf-9 cells using anti-FMDV VP1 (aa 135–160) mouse antiserum. Chimeric NS1-FMDV protein (lane a) was recognized but
not the wild-type NS1 protein (lane b).
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amined by electron microscopy, both types of chimeric
particles exhibited similar morphology and were identi-
cal to those made by wild-type NS1 and morphologically
identical to that found in infected cells (Fig. 3). These
data indicate no loss of the tubule structure upon isola-
tion, an important factor for scale up and use as an
immunogen delivery system.
Chimeric tubules can stimulate CD4 T cell
proliferation
The T cell responses to an immunogen can be defined
with synthetic peptides specific for each mouse haplo-
type and through isolation of responsive T cells as CD4
T cell clones for in vitro study of their specificity. In
FIG. 2. Distribution of wild-type and chimeric NS1 protein. (A) Wild-type tubules (a), chimeric NS1-influenza A HA (aa 186–205) tubules (b), and
NS1-FMDV VP1 (aa 135–144) tubules (c) were analyzed by SDS–10% PAGE following 10–40% continuous sucrose gradient centrifugation. Infected Sf-9
cell extracts were resolved by sucrose gradient centrifugation and a total of seven (1.5 mL each) fractions obtained thereof (designated 1, top; 7,
bottom; P, pellet) were analyzed by 10% SDS–PAGE. Large accumulations of proteins in lanes 3–7 are clearly evident which were collected for further
characterization. The purified NS1 protein as control (lane C) is included in each. (B) Sucrose gradient purified wild-type NS1 tubules (a), purified
chimeric NS1-FMDV VP1 (135–144) (lane b), and NS1-Flu HA (186–205) (lane c) tubules as resolved in 10% SDS–PAGE gels are shown. Relatively larger
size of chimeric proteins are distinctly evident.
FIG. 3. Electron micrographs of purified tubules. Sucrose gradient purified wild-type NS1 tubules (A) and chimeric tubules carrying influenza virus
HA epitope (B) showing essentially similar morphology.
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addition, in vitro binding of synthetic peptides to MHC
class II antigens correlates with in vivo defined T cell
recognition specificity (Benjamin et al., 1984). The major-
ity of HA-specific CD4 T cell clones derived from influ-
enza X31 virus (H3N2 subtype) infected C57BL/10 (H-2b)
mice have been shown to recognize a unique HA epitope
that encompasses amino acid residues 186–205 (Barnett
et al., 1989a,b). Such HA-specific T cell clones can be
used to assess the immune response to the chimeric
NS1-HA construct in an in vitro T cell proliferation assay.
T cell lines were established from the spleens of indi-
vidual BALB/c mice primed by intranasal infection with
X31 virus (5HAU) and HA-specific T cell clones were
isolated from these B10 (H-2b) mice and maintained as
described previously (Barnett et al., 1989a,b).
To assess if the NS1-HA chimeric tubules could in-
duce immune responses, we used the HA-specific T cell
clones for a comparison of their proliferative activity with
wild-type tubules and HA peptide. When proliferative
responses of isolated clones to the NS1-chimera were
compared with the control peptide (HA aa 186–205) at
different doses, the chimera significantly stimulated the
proliferation of CD4 T cell clones (see Fig. 4). The data
indicated that the peptide presented by the chimeric NS1
tubule was recognized by CD4 T cell clones from MHC
matched donors. No such response was obtained with
purified wild-type tubules in a parallel experiment, indi-
cating that the proliferative response obtained with the
chimeric construct was specific (see Fig. 4). Interestingly,
the construct could also stimulate MHC-mismatched
CD4 T cell clones, albeit to a lesser extent than the
MHC matched samples, but to a significantly higher level
than peptide alone (see Fig. 4). These data show that
influenza A HA (186–205) epitope is recognized effi-
ciently in a dose-dependent manner by at least two MHC
haplotypes (H-2b, Fig. 4, left and H-2d, Fig. 4, right) when
displayed on the surface of the NS1 tubules.
Stimulation of IFN- production by chimeric tubules
The immune response to chimeric tubules was con-
firmed by an alternative assay for T cell activation
marked by the release of IFN-. Chimeric tubules stim-
ulated the release of IFN- from a CD4 clone derived
from C57BL/10 (H-2b) mice as did free HA (186–205)
peptide (Fig. 5, top), but not the peptides HA1 48–67 and
HA1 68–83, as reported previously (data not shown;
Barnett et al., 1989a). Recombinant tubules were be-
tween two to four times better than free peptide on a
weight-to-weight basis in stimulating IFN release (Fig. 5,
based on 2.5 and 5 g samples). Taking into account the
relative molecular weight of the NS1 chimera (64 kDa)
and peptide (2 kDa), stimulation by NS1 peptide was
100-fold better when calculated on a mole equivalence
basis. Some activation of MHC mismatched (H-2d)
clones was also apparent (Fig. 5, bottom), although the
release of IFN- was at a much lower level. As expected,
no response was obtained when wild-type recombinant
tubules were used as control (Fig. 5, top and bottom).
Taken together with the proliferation data and taking into
account the difference in molecular weight of the free
peptide and NS1 chimera, it is clear that the chimeric
tubule stimulated CD4 T cell clones more efficiently on
a mole-to-mole basis if the epitope was presented as
part of a multivalent chimeric tubules than as peptide
alone.
FIG. 4. Proliferative responses of T cell clones to chimeric tubules. Proliferation assays for T cell clones derived from each of two strains of mice
(BALB/c, right and BH10, left) stimulated by either free peptide (diamonds) or NS1-peptide fusion proteins (squares) or wild-type (wt) NS1 tubules
(circle). Assays were performed in triplicate and the results represent the arithmetic mean of [3H]thymidine incorporation for the cultures. Data shown
are the results of three different experiments, each of which varied by no more than 10%.
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Chimeric tubules elicit protective immune response in
mice
The region between residues aa 135 and 144 of VP1
contains natural immunodominant B and T cell epitopes.
It has been reported previously that three different ani-
mal species, cattle (Zamorano et al., 1994), mice (Zamo-
rano et al., 1995), and guinea pig (Zamorano et al., 1998),
strongly recognized this region. However, immunization
of mice or cattle with this peptide alone completely failed
to elicit any immune response. Only when coupled to
bovine serum albumin (BSA) was the peptide able to
elicit a FMDV-specific response. The same was true
when p135–144 peptide was used as a dimer (Zamorano
et al., 1995, 1998). Based on this observation, we ex-
plored whether NS1 tubules carrying a single-copy pep-
tide p135–144 could elicit an appropriate immune re-
sponse against the VP1 peptide or more importantly the
virus, and furthermore, whether such a response in turn
had any protective efficacy against virulent virus chal-
lenge.
A group of seven BALB/c mice was immunized and
boosted twice with a 50 g/dose of either chimeric or
wild-type tubules intraperitoneally. Ten days after the last
booster, animals were bled and the sera analyzed for the
presence of anti-FMDV antibodies. The experiment was
independently performed four times. Antibodies raised in
immunized mice with chimeric tubules showed signifi-
cant antibody response against VP1 as demonstrated by
their reactivity to aa 135–160 peptide in ELISA (see Fig.
6). Equally strong antibody responses were obtained
when intact FMDV particles were used as antigen in
ELISA. In contrast, sera from mice immunized with wild-
FIG. 5. Stimulation of IFN- production by chimeric tubules. Interferon gamma, measured by ELISA assay, present in the culture supernatant from
T cell clones derived from BALB/c and BH10 mice upon stimulation with free peptide, NS1-fusion protein, wild-type (wt) NS1 tubules. Values are the
mean of three independent experiments in each of which in vitro stimulation was carried out in triplicate. Note the figures are not corrected for molar
equivalence (NS1-peptide fusion proteins being 30 the molecular weight of free peptide).
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type tubules showed no reactivity against either the VP1
or the intact virions, indicating that the immune response
induced by the NS1.FMDV tubules was specific.
To assess whether the immunity developed in each
animal was sufficient to confer protection against virus
infection, each immunized mouse was challenged with
104 lethal doses (SMLD50) of FMDV O1 Campos intraperi-
toneally (Zamorano et al., 1998). It has been shown pre-
viously that intraperitoneal inoculation of 104 SMLD50 in
most mouse strains replicates intensively in its major
target organ, the pancreas, within 36–48 h and by 48–72
h has accumulated a high titer viremia (5 to 7 logs of
virus). However, the presence of a protective immune
response aborts virus replication in the pancreas and
prevents the appearance of viremia. Thus, protected
mice do not develop viremia at any time postinfection,
while nonimmune mice suffer a pancreatic infection and
viremia. Viremia is easily detected by inoculating suck-
ling mice, perhaps the most sensitive system for detect-
ing infectious FMDV other than the intradermal inocula-
tion in cattle. The protocol for detecting the presence of
viremia in adult mice has been developed to form a
robust assay (Zamorano et al., 1995; Wigdorovitz et al.,
1999; Dus Santos et al., 2000). Therefore, protection af-
forded by the chimeras was determined by the absence
of viremia in the blood samples of the challenged mice at
36 h postinfection. Viremia was assessed by intramus-
cular (im) inoculation of 50 l/mice of a 1/100 dilution of
peripheral blood samples of the challenged animals in 5-
to 6-day-old newborn BALB/c mice and the presence of
viremia was indicated by death of the animal. When the
peritoneal blood samples of the challenged mice were
tested for viremia in a group of newborn mice (Zamorano
et al., 1995), 60% of the mice survived, indicating that the
inoculated blood samples lacked the presence of FMDV.
Thus, the surviving animals receiving the chimeric tu-
bules had generated a sufficient immune response that
protected them against the FMDV challenges. In con-
trast, the mice that were immunized with wild-type NS1
tubule preparation were infected with FMDV after the
challenge, as the newborn mice died when inoculated
with the blood samples containing the virus. The animal
experiments were repeated four times to ensure the
specificity of the protective response of the chimeric
tubules.
DISCUSSION
Efficient presentation of an immunogenic epitope by
polyvalent particulate structure has evoked considerable
interest in recent years. The epitopes of interest in these
cases are linked to a carrier protein, which can assem-
ble into a predictable multimeric structure and present
the carried foreign antigenic sequence to the immune
system. Examples of molecules that have been used for
this approach include, among others, hepatitis B surface
antigen (HbsAg) (Delpeyroux et al., 1986) yeast Ty-like
particles (Adams et al., 1987), poliovirus (Evans et al.,
1989), hybrid human immunodeficiency virus Gag parti-
cles (Griffiths et al., 1993), and parvovirus-like particles
(Miyamura et al., 1994). Similarly we have demonstrated
the potential of virus-like particles based on icosahedral
BTV core structure for the delivery of foreign epitopes
(French and Roy, 1990; Belyaev and Roy, 1993; LeBlois
and Roy, 1993; Adler et al., 1998). One of the limitations of
BTV particles and other icosahedral particle-based vec-
tors is their inability to accommodate larger sequences,
which perturb the assembly of the capsid structure. In
contrast, BTV-TUBs for their characteristic helical config-
uration can accommodate larger sequences, even a
complete antigen such as green fluorescent protein
(GFP) (Ghosh et al., 2002a) and are therefore likely to
carry and deliver conformational epitopes. Thus, these
particulate structures made by NS1 have important im-
plications for novel vaccine design. An additional advan-
tage of these tubules is that the level of expression of
recombinant NS1 in infected Sf cells is extremely high
(300 mg/L culture), which is highly desirable for devel-
opment of candidate vaccine (Urakawa and Roy, 1988). In
addition, tubules are relatively easy to purify and, due to
their size, mice immunized with these tubules in the
absence of adjuvants generated a high titer of antibody
comparable to those obtained using standard adjuvant
protocols (M. K. Ghosh, Z. Moldeavenu, and P. Roy, un-
published observation).
FMDV is the causative agent of a very significant
economic disease affecting meat and milk-producing
domestic animals (Brown et al., 1992). The structural
protein VP1 of FMDV carries critical epitopes and ex-
pression of the immunogenic areas of VP1 in heterolo-
FIG. 6. NS1-FMDV chimeric tubules induce an anti-FMDV response.
Approximately 10 g of NS1-VP1 tubules were used to immunize each
of a group of seven BALB/c mice. Following two boosts at two-week
intervals, the mice were bled and the presence of antibodies to FMDV
was assessed by an ELISA using FMDV virions or VP1 peptide as the
test antigen. The response was compared to the preimmune serum
from each mouse.
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gous systems generated experimental immunogens
which could protect experimental and natural hosts
(Kleid et al., 1981; DiMarchi et al., 1988; Morgan and
Moore, 1989; Zamorano et al., 1998). The VP1 sequence
that we have used to generate chimeric tubules had
previously been shown to constitute the shortest amino
acid sequence of VP1 that had the ability to induce a
protective anti-FMDV immune response (Carrillo et al.,
1998; Zamorano et al., 1994, 1998). In these reports, a
decamer (aa 135–144 epitope) of VP1, used as a syn-
thetic peptide, elicited a protective neutralizing antibody
response only when presented as a dimer. In the
NS1.VP1 construct designed here, the aa 135–144
epitope is expressed as a single copy and as a C-
terminal fusion protein of BTV NS1 formed tubules.
These tubules were able to induce a specific anti-FMDV
antibody response, which protected 60% of the immu-
nized mice. Although the protective antibody response
was relatively weak, it is the first evidence that demon-
strated that a single-copy FMDV VP1 (aa 135–144)
epitope, expressed as a fusion protein, could protect
immunized mice against a virulent FMDV challenge. It is
therefore quite conceivable that an improved design of
an NS1 construct(s) that includes the adjacent flanking
amino acid residues of the aa 135–144 region of VP1
and/or in presence of appropriate adjuvant may enhance
the immune response. It is highly likely that the immu-
nogenicity conferred by the chimeric tubules is probably
due to the polyvalent nature of the antigen that may be
important in cross-activation of immune cells.
The CD4 T cells are primarily helper T cells providing
help both to B cells for antibody production and to class
I restricted CD8 CTLs for their proliferation. The impor-
tant role of CD4 T cells in immunity to influenza virus
infection is well documented. CD4-deficient mice have
been shown to develop impaired immunity to influenza
virus (Nguyen et al., 2001). It has also been noted, how-
ever, that CD4 T cells alone are unable to clear virus
and to promote recovery from primary infection (Mozdza-
nowska et al., 1997; Topham and Doherty, 1998; Doherty
et al., 1997) and have shown that during influenza virus
infection CD4 T cells are important for providing help for
B cells and antibody responses. The importance of B
cells in generating heterosubtypic immunity to influenza
A virus has also been documented recently (Nguyen et
al., 2001). It is also interesting to note that the helper T
cells specific for M or NP antigens can provide help to B
cells secreting HA antibody, and in the same manner,
can augment the antibody response to protective anti-
gens. The data that we have presented here clearly
showed the chimeric NS1 tubules containing the appro-
priate epitope could indeed induce HA peptide specific
CD4 T helper cell response of influenza A virus. Evi-
dently chimeric tubules which include both B cell
epitopes along with CD4 Th epitope would enhance
strong influenza A virus humoral responses. In addition,
inclusion of CTL epitopes to generate antiinfluenza cy-
totoxic responses may then complement such attempts.
Indeed we have already shown that chimeric NS1 tu-
bules can induce protective lymphocytic choriomeningi-
tis virus (LCMV) specific class I restricted CD8 CTL
response (Ghosh et al., 2002a). To rationalize the hypoth-
esis that more than one epitope can be used to generate
chimeric tubules which will in turn induce immune re-
sponses against each type of epitopes, we have recently
generated tubules containing two HLA-A2-restricted hu-
man melanoma epitopes in tandem. We have obtained
evidence that such chimeric tubules were capable of
inducing CTL responses against both epitopes simulta-
neously in vivo in HLA-A2 transgenic mice (Ghosh et al.,
2002b).
It seems quite reasonable therefore to hypothesize
that, based on our accumulated data, BTV-derived chi-
meric tubular structures carrying broad spectrum multi-
ple immunogenic epitopes would be highly effective
against human pathogens which require both cellular
and humoral responses to overcome infection.
MATERIALS AND METHODS
Viruses and cells
Spodoptera frugiperda cells were grown in suspen-
sion or monolayer cultures at 28°C in SF-900 II serum-
free medium (Gibco-BRL). Derivatives of Autographica
californica nuclear polyhedrosis virus (AcNPV) contain-
ing the wild-type BTV-10 NS1 gene (Ac10BTV6) and chi-
meric NS1 mutant were plaque purified and propagated
as described previously (Brown and Faulkner, 1977).
Mice
All animal experiments were carried out in 60- to
90-day-old male BALB/c (H-2d/d) mice bred in our own
colony. Detection of viremia in challenged animals was
performed in 5- to 6-day-old BALB/c mice litters.
Cell lines and clones
The generation of the HA-specific, CD4 T cell clones
used in this study has been described elsewhere (Bar-
nett et al., 1989b). Briefly, T cell clones were established
by limiting dilution from lines from the spleens of indi-
vidual BALB/c donors primed by intranasal infection with
X31 virus. T cell clones were maintained by restimulation
with X31 virus (100 HAU/mL) and irradiated (3000 rad)
syngeneic spleen cells (2  106/mL) as feeder cells
every 10–12 days, with the addition of interleukin-2
(IL-2)-containing supernatant (prepared from concanava-
lin A stimulated rat spleen cells) and feeder cells, 3 days
after antigen.
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Chimeric mutation of the BTV-10 NS1 gene and
construction of recombinant transfer vector
Oligonucleotide 5-CT AGT AGC TAC AGC AGA AAT
GCT GTG CCC AAC GTG-3 and its complementary were
designed to encode FMDV O1 Campos B-T cell epitope
(residues 135–144 of the G-H loop of VP1 protein) (Zamo-
rano et al., 1998). Similarly, oligonucleotide 5-CT AGT AGC
ACG AAC CAA GAA CAA ACC AGC CTG TAT GTT CAA
GCA TCA GGG AGA GTC ACA GTC TCT-3 and its comple-
mentary were designed to encode the influenza A HA T
helper cell epitope of residues HA (186–205) (Barnett et al.,
1989a,b). A 5 overhang CT AGT was designed for forward
sense and a 3 A for the reverse-sense oligonucleotide,
respectively, for insertion into SpeI and SmaI cut
pAcYM1NS1SpSm transfer vector. The oligonucleotides
were obtained from Amitof Biotech (Boston, MA), phosphor-
ylated with T4 polynucleotide kinase, and annealed at 55°C
for 3 min. The annealed oligonucleotides were then ligated
into SpeI- and SmaI-digested pAcYM1NS1SpSm [which
contains the BTV-10 NS1 gene engineered at the carboxy-
terminus to incorporate SpeI and SmaI sites between the
last amino acid Y (552) and the stop codon], to generate the
recombinant transfer vectors pNS1SpSm. FMDV.VP1 (135–
144) and pNS1SpSm.Flu HA (186–205), respectively. The
sequence of the inserted oligonucleotides was then con-
firmed by the dideoxynucleotide technique (Sanger et al.,
1977) with incorporation of [35S]dATP, using a sequenase
version 2.0 DNA sequencing kit (U.S. Biochemical). The
forward primer (HL3) is some 96 nucleotides upstream of
NS1 stop codon, while the reverse primer (Bac2) corre-
sponds to a region of the AcNPV genome that is some 60
nucleotides downstream of the NS1 insertion site and rep-
resents the sequence in the opposing DNA strand.
Isolation of recombinant baculoviruses
The lipofectin technique (Felgner et al., 1987) was used to
cotransfect monolayers of Sf-9 cells with the recombinant
transfer vector and Bsu36I triple-cut AcNPV DNA (Kitts and
Possee, 1993). Recombinant baculoviruses were selected
on the basis of their lacZ-negative phenotypes, plaque
purified, and propagated as described elsewhere (King and
Possee, 1992). From pNS1SpSm.FMDV.VP1 (135–144) the
recombinant AcNS1.FMDV VP1 (135–144) virus was iso-
lated. Similarly from pNS1SpSm.Flu.HA (186–205) the re-
combinant AcNS1.Flu HA (186–205) virus was isolated.
Detection of chimeric proteins
Expressed chimeric proteins in Sf cells were visual-
ized by sodium dodecyl sulfate–polyacrylamide gel elec-
trophoresis (SDS–PAGE) and Coomassie blue staining.
For Western blot analyses, resolved proteins from gels
were transferred to an immobilon-P membrane (Milli-
pore, Bedford, MA) by standard blotting procedure and
probed with either anti-NS1 or anti-FMDV VP1 (p135–160)
mouse antiserum for 2 h at 37°C. The membrane was
then washed and incubated with an alkaline phospha-
tase labeled anti-mouse IgG rabbit antiserum (Dako-
patts) for 1 h at 37°C and washed three times and the
reaction developed by the addition of the substrate NBT/
BCIP.
Purification of tubules
Baculovirus-expressed chimeric mutant BTV-10 NS1
tubules were purified as described previously (Urakawa
and Roy, 1988; Monastyrskaya et al., 1995). Sf-9 cells
were infected in suspension culture with recombinant
AcNPV viruses using a m.o.i. of 5. After incubation at
28°C for 72 h, cells were harvested, washed with PBS,
resuspended in STE buffer (150 mM NaCl, 1 mM EDTA,
10 mM Tris–HCl, pH 7.5) containing 0.5% v/v Triton X-100,
and lysed by homogenization. The lysate was clarified by
centrifugation (5 min at 3500 rpm) and the supernatant
loaded onto a cushion of 3 ml of 40% (w/v) sucrose in
STE and centrifuged in a SW41 rotor (2 h at 35,000 rpm).
The resulting pellet was resuspended in a small volume
of STE and loaded onto a 10–40% gradient of sucrose in
STE and centrifuged in a SW28 rotor (1 h at 19,000 rpm).
The gradient was fractionated (1.5 ml) and the pellet and
each fraction were analyzed by SDS–PAGE for the pres-
ence of chimeric NS1.
Electron microscopy
Sucrose gradient purified wild-type and chimeric NS1
tubules in STE buffer were adsorbed onto carbon-coated
copper 400-mesh electron microscopy grids for 2–3 min,
washed with water, and negatively stained with 2% (w/v)
phosphotungstic acid. Grids were examined with a Hita-
chi H7000 electron microscope at 75 kV. For in situ
localization of tubules, cells infected with recombinant
baculoviruses expressing either wild-type or chimeric
mutant NS1 were fixed in 1% glutaraldehyde and embed-
ded in Epon for sectioning. Sections on grids were then
stained with lead citrate and uranyl acetate.
T cell proliferation assays
T cell proliferation assays were performed in triplicate
in 200-L volumes in 96-well microtiter plates as de-
scribed previously by Barnett et al. (1989a,b). In brief, 2
104 were incubated with antigen-presenting cells [APC;
irradiated (3000 rad) syngeneic spleen cells (4  105)]
together with chimera, peptide, or medium alone for 72 h
for 37°C, pulsed for a further 6 h with [3H]thymidine
(3H-TdR; 1 Ci/ml), and acid-perceptible radioactivity de-
termined. The results represent the arithmetic mean of
[3H] incorporation for triplicate cultures and were repro-
ducible in three or more independent determinations.
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Measurement of IFN-
The level of IFN- in culture supernatants was moni-
tored by ELISA using standard protocol. In brief, 96-well
plates were coated with 1 g/ml (100 l) anti-IFN-
monoclonal antibody diluted in NaCO3 at pH 8.3 and
incubated overnight at 4°C. The wells were then blocked
with 200 l 3% bovine serum albumin (BSA) in phos-
phate-buffered saline (PBS)–Tween for 2 h at room tem-
perature. Conditioned culture media from stimulated
clones (100 L) were added to duplicate wells and incu-
bated overnight at 4°C. The wells were washed with
PBS–Tween and incubated with 1 g/ml biotinylated
anti-IFN- monoclonal antibody diluted in 1% BSA in
PBS-Tween for 1 h. After four washes, the wells were
incubated for 1 h with HRP-streptavidin diluted in PBS
and developed with 1.1 mmol/L 2,2-azino-bis(3-ethyl-
benz-triazoline-6-sulfonic acid in 0.1 mol/L citrate-phos-
phate buffer (pH 4.2) containing 0.01% H2O2. Standard
curves were generated using human recombinant forms
of IFN-). The limits of detection of the ELISA assay were
50 pg/ml.
Analysis of antibody response to NS1 FMDV VP1
(135–144)
BALB/c mice were immunized intraperitoneally (i.p.) on
days 0, 15, 30, 45, 60, and 75 with either NS1 tubules
expressing VP1 (135–144) or wild-type NS1 tubules (10
g of protein in incomplete Freund’s adjuvant per animal
per injection). The antibody response was measured by
a direct ELISA using a synthetic peptide p135–160 (which
represents the amino acid residues of FMDV VP1 O1C
between positions 135–160) or FMDV particles as an
antigen (Zamorano et al., 1998). Ninety-six-well Immulon
2 ELISA plates (Dynatech) were coated with 10 g/ml of
p135–160 diluted in carbonate buffer pH 9.6 for 12 h at
4°C. Plates were then washed three times with PBS
containing 0.025% Tween 20 (PBST) and blocked with 3%
horse serum in PBST for 1 h at 37°C (all subsequent
steps were performed using this buffer). Then, a fourfold
dilution of mouse sera to be tested was added and
incubated for 1 h at 37°C. Plates were washed three
times with PBST and incubated for 1 h at 37°C with
peroxidase-labeled rabbit anti-mouse IgG antibodies
(Dakopatts). After three washes, the reaction was devel-
oped by addition of O-phenylenediamine-H2O2 in citrate
buffer pH 5 and read 10 min later at 490 nm in an MR 500
Microplate Reader (Dynatech). Sera were individually
tested in a fourfold dilution series in blocking buffer.
Serum titres are expressed as the log of the reciprocal of
the highest serum dilution which present optical density
(OD) readings above the mean OD readings  3SD of
sera from five animals immunized with wild-type NS1
tubules.
Challenge experiments
Mice were challenged with 104 SMLD50 intraperitone-
ally of FMDV O1 Campos (Zamorano et al., 1998). Pro-
tection was determined by the absence of viremia in the
challenged mice at 48 h postinfection. Viremia was
tested by intramuscular inoculation of 50 l/mice of a
1/10 dilution of peripheral blood to 5- to 6-day-old litter
mice, six mice per blood sample.
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